Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313857729> ?p ?o ?g. }
- W4313857729 endingPage "141" @default.
- W4313857729 startingPage "134" @default.
- W4313857729 abstract "To present our real-life experience with dabrafenib and trametinib (D-T) treatment in patients with BRAF V600E-mutated ATC in Argentina. We included five patients from four different hospitals. The median age was 70 years, and 60% were male. The performance status at diagnosis was grade 0 in 60% and grade 2 in 40% of patients. Four patients could undergo total thyroidectomy; in one of them, surgical treatment was amenable due to the indication of D-T as neoadjuvant therapy. From the total cohort, the best response to treatment was complete response in 40%, partial response in 20%, and stable disease in 20%. The median duration of response was 20 weeks, ranging from 16 to 92 weeks. All patients experienced at least one adverse event (AE). Grade ≥3 AEs were observed in two (40%) patients. They were upper gastrointestinal bleeding and subclavian vein thrombosis. The median follow-up was 20 weeks (range: 16 to 92). This report contributes to illustrate the feasibility and effectiveness of D-T treatment in five patients with loco-regionally advanced and metastatic BRAF V600E-mutated ATC in a real-life setting. A multidisciplinary approach and rapid molecular-tailored testing are essential to begin this therapeutic option." @default.
- W4313857729 created "2023-01-10" @default.
- W4313857729 creator A5011987350 @default.
- W4313857729 creator A5022615023 @default.
- W4313857729 creator A5025400193 @default.
- W4313857729 creator A5033156236 @default.
- W4313857729 creator A5050051207 @default.
- W4313857729 creator A5055373420 @default.
- W4313857729 creator A5060436512 @default.
- W4313857729 creator A5062064935 @default.
- W4313857729 creator A5064164870 @default.
- W4313857729 creator A5067746841 @default.
- W4313857729 creator A5083407153 @default.
- W4313857729 creator A5087938444 @default.
- W4313857729 creator A5090678002 @default.
- W4313857729 date "2023-01-09" @default.
- W4313857729 modified "2023-10-16" @default.
- W4313857729 title "Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience" @default.
- W4313857729 cites W1893807782 @default.
- W4313857729 cites W1971381075 @default.
- W4313857729 cites W1982685948 @default.
- W4313857729 cites W1991662589 @default.
- W4313857729 cites W1998915601 @default.
- W4313857729 cites W2010046334 @default.
- W4313857729 cites W2017251306 @default.
- W4313857729 cites W2035106853 @default.
- W4313857729 cites W2038838156 @default.
- W4313857729 cites W2046441495 @default.
- W4313857729 cites W2076668534 @default.
- W4313857729 cites W2083294133 @default.
- W4313857729 cites W2108668400 @default.
- W4313857729 cites W2111520932 @default.
- W4313857729 cites W2112400388 @default.
- W4313857729 cites W2113134419 @default.
- W4313857729 cites W2139947894 @default.
- W4313857729 cites W2160405811 @default.
- W4313857729 cites W2279570938 @default.
- W4313857729 cites W2280062645 @default.
- W4313857729 cites W2502134830 @default.
- W4313857729 cites W2535032472 @default.
- W4313857729 cites W2544712280 @default.
- W4313857729 cites W2736254713 @default.
- W4313857729 cites W2763103003 @default.
- W4313857729 cites W2766581537 @default.
- W4313857729 cites W2895923730 @default.
- W4313857729 cites W2945012518 @default.
- W4313857729 cites W2963699363 @default.
- W4313857729 cites W2975387808 @default.
- W4313857729 cites W3008107700 @default.
- W4313857729 cites W3016136761 @default.
- W4313857729 cites W3024922118 @default.
- W4313857729 cites W3027512319 @default.
- W4313857729 cites W3038433057 @default.
- W4313857729 cites W3047570563 @default.
- W4313857729 cites W3080978633 @default.
- W4313857729 cites W3137149901 @default.
- W4313857729 cites W3157882994 @default.
- W4313857729 cites W4205515761 @default.
- W4313857729 doi "https://doi.org/10.1007/s12020-022-03295-2" @default.
- W4313857729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36617605" @default.
- W4313857729 hasPublicationYear "2023" @default.
- W4313857729 type Work @default.
- W4313857729 citedByCount "2" @default.
- W4313857729 countsByYear W43138577292023 @default.
- W4313857729 crossrefType "journal-article" @default.
- W4313857729 hasAuthorship W4313857729A5011987350 @default.
- W4313857729 hasAuthorship W4313857729A5022615023 @default.
- W4313857729 hasAuthorship W4313857729A5025400193 @default.
- W4313857729 hasAuthorship W4313857729A5033156236 @default.
- W4313857729 hasAuthorship W4313857729A5050051207 @default.
- W4313857729 hasAuthorship W4313857729A5055373420 @default.
- W4313857729 hasAuthorship W4313857729A5060436512 @default.
- W4313857729 hasAuthorship W4313857729A5062064935 @default.
- W4313857729 hasAuthorship W4313857729A5064164870 @default.
- W4313857729 hasAuthorship W4313857729A5067746841 @default.
- W4313857729 hasAuthorship W4313857729A5083407153 @default.
- W4313857729 hasAuthorship W4313857729A5087938444 @default.
- W4313857729 hasAuthorship W4313857729A5090678002 @default.
- W4313857729 hasBestOaLocation W43138577291 @default.
- W4313857729 hasConcept C121608353 @default.
- W4313857729 hasConcept C126322002 @default.
- W4313857729 hasConcept C141071460 @default.
- W4313857729 hasConcept C143998085 @default.
- W4313857729 hasConcept C184235292 @default.
- W4313857729 hasConcept C197934379 @default.
- W4313857729 hasConcept C2776131300 @default.
- W4313857729 hasConcept C2778472372 @default.
- W4313857729 hasConcept C2778822529 @default.
- W4313857729 hasConcept C2778830669 @default.
- W4313857729 hasConcept C2779134260 @default.
- W4313857729 hasConcept C2779699572 @default.
- W4313857729 hasConcept C2779761222 @default.
- W4313857729 hasConcept C2780256643 @default.
- W4313857729 hasConcept C2994587330 @default.
- W4313857729 hasConcept C57074206 @default.
- W4313857729 hasConcept C71924100 @default.
- W4313857729 hasConcept C72563966 @default.
- W4313857729 hasConcept C86803240 @default.